Hadean Ventures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Complement Therapeuticscomplementtx.comApr 2023
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsCambridge Innovation CapitalSeroba Life SciencesBGVBioGeneration VenturesForbionGimv+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.